​​​
  1. Hold Biocon; Q1 profit weak excluding one-off gain: HSBC

Hold Biocon; Q1 profit weak excluding one-off gain: HSBC

Biocon reported Q1FY16 net profit Rs 12,620 crore.

By: | Updated: July 28, 2015 9:05 AM
Biocon Sebi

Biocon reported Q1FY16 net profit Rs 12,620 crore. (Reuters)

Biocon reported Q1FY16 net profit Rs 12,620 crore (23% y-o-y). This includes Rs 4,500 crore of one-time payment from Merck against cancellation of clause for capacity reservation fee for fidaxomicin supply. Adjusting for this one-off, net profit at Rs 8120 crore (-21.1% y-o-y) were 27.5% & 21.5% lower than HSBCe & consensus. Core revenues at Rs 790 crore (9.7% yoy) were 4.4% below HSBCe due to weak BioPharma (ex-licensing income) and India formulations sales. Ebitda margins at 21.2% were c220bps below HSBCe due to higher material, staff & R&D expenses. The company booked forex gain of Rs 650 crore during Q1FY16.

Core biopharma sales at Rs 420 crore were broadly flat on y-o-y basis due to limited product supply on planned facility shut-down for maintenance. We expect sales to pick up as insulin & biosimilars gain traction in emerging markets as its Malaysia facility is on track to start commercial sales from 2016. India branded formulations sales at Rs 110 crore were flat y-o-y but grew 14% q-oq as the company continues to rationalise its product portfolio as a part of its strategic shift to specialty segments. Biocon stated that this segment is on track to achieve 20% sales contribution by 2019 (currently 14%).

We maintain hold and view announced IPO of subsidiary Syngene as potential value unlocking catalyst. Our revised fair value target price is R431.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Tags: Biocon

Go to Top